Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma

Area of Science:

• Oncology
• Immunotherapy
• Medical Imaging

Background:

• Pancreatic adenocarcinoma remains a challenging cancer with limited treatment options.
• Targeting extracellular matrix metalloprotease inducer (EMMPRIN) and death receptor 5 (DR5) are potential therapeutic strategies.
• Multimodal imaging can assess treatment efficacy and drug distribution.

Purpose of the Study:

• To evaluate the efficacy of combined EMMPRIN- and DR5-targeted therapy for pancreatic cancer.
• To assess the impact of combination therapy on tumor growth and drug delivery using multimodal imaging.
• To investigate the in vitro and in vivo activity of anti-EMMPRIN and anti-DR5 (TRA-8) antibodies.

Main Methods:

• In vitro cytotoxicity assays (ATPlite) and fluorescence imaging were used to analyze antibody efficacy and distribution in pancreatic cancer cell lines (MIA PaCa-2, PANC-1).
• Orthotopic pancreatic tumor models in severe combined immunodeficient mice were established for in vivo studies.
• Multimodal imaging techniques including dynamic contrast-enhanced MRI, SPECT/CT with Tc-99m-labeled TRA-8, and PET/CT with (18)F-FDG were employed.

Main Results:

• TRA-8 antibody demonstrated significant in vitro cytotoxicity against both cell lines, with signal intensity correlating with efficacy.
• Anti-EMMPRIN therapy enhanced the tumor delivery of an MR contrast agent but not Tc-99m-labeled TRA-8.
• Combination therapy significantly suppressed tumor growth in both MIA PaCa-2 and PANC-1 models, exhibiting an additive effect.

Conclusions:

• Combined EMMPRIN- and DR5-targeted therapy shows significant potential for treating pancreatic adenocarcinoma.
• Multimodal imaging is valuable for evaluating therapeutic responses and drug delivery in preclinical models.
• The combination therapy exhibits an additive effect, suggesting a promising therapeutic approach for pancreatic cancer.